Enveric Biosciences Inc. (ENVB) Financial Statements (2024 and earlier)

Company Profile

Business Address 4851 TAMIAMI TRAIL N, SUITE 200
NAPLES, FL 34103
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,28817,72417,3561,5784311,371
Cash and cash equivalents2,28817,72417,3561,5784311,371
Receivables     6,3847,871
Prepaid expense455     
Deferred costs568     
Other current assets     784819
Other undisclosed current assets271708381701  
Total current assets:3,58218,43217,7372,2797,59910,061
Noncurrent Assets
Operating lease, right-of-use asset  64176  
Property, plant and equipment507677294 8359
Intangible assets, net (including goodwill)211(9,332)8,5121,81817,31419,508
Goodwill  (9,712)1,588 13,73013,730
Intangible assets, net (excluding goodwill)2113806,9241,8183,5845,778
Deferred income tax assets     9
Other undisclosed noncurrent assets  9,712   9
Total noncurrent assets:7181,1218,9821,81817,40619,576
TOTAL ASSETS:4,30019,55326,7194,09725,00529,637
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,2942,1691,293 1,9901,698
Interest and dividends payable  219172
Taxes payable  648182
Employee-related liabilities  738950
Accounts payable1,219463    
Accrued liabilities1,0761,7061,293 149109
Other undisclosed accounts payable and accrued liabilities     236283
Debt     8,7625,214
Derivative instruments and hedges, liabilities  727    
Other liabilities24851    
Other undisclosed current liabilities25249791 3,6327,778
Total current liabilities:2,3443,9962,084 14,38414,689
Noncurrent Liabilities
Long-term debt and lease obligation:   69   
Operating lease, liability   69  
Other undisclosed noncurrent liabilities   2,192  4,189
Total noncurrent liabilities:   2,330  4,189
Other undisclosed liabilities    681  
Total liabilities:2,3443,9964,41368114,38418,878
Temporary equity, carrying amount  885    
Equity
Equity, attributable to parent1,95614,67222,3063,41610,62210,759
Preferred stock    3344
Common stock272132610125423
Additional paid in capital100,81694,39682,74715,22351,04044,723
Accumulated other comprehensive income (loss)(570)(537)(31)(181)6087
Accumulated deficit(96,500)(79,208)(60,736)(11,760)(40,508)(34,478)
Stockholders' equity note, subscriptions receivable (1,818)     
Total equity:1,95614,67222,3063,41610,62210,759
TOTAL LIABILITIES AND EQUITY:4,30019,55326,7194,09725,00529,637

Income Statement (P&L) ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues     39,91542,998
Cost of revenue     (31,764)(34,015)
Gross profit:     8,1518,984
Operating expenses(16,448)(27,415)(64,623)(5,617)(14,476)(16,130)
Operating loss:(16,448)(27,415)(64,623)(5,617)(6,325)(7,146)
Nonoperating income (expense)(814)7,4588,1921,2471,110(3,403)
Investment income, nonoperating2093,473    
Interest and debt expense  (5)(10)(445)(691)(730)
Loss from continuing operations before equity method investments, income taxes:(17,263)(19,963)(56,442)(4,815)(5,906)(11,279)
Other undisclosed income from continuing operations before income taxes  510 691730
Loss from continuing operations before income taxes:(17,263)(19,957)(56,432)(4,815)(5,215)(10,549)
Income tax expense (benefit)(29)1,4867,455 (389)(6,349)
Loss from continuing operations:(17,292)(18,471)(48,977)(4,815)(5,604)(16,898)
Loss before gain (loss) on sale of properties:(48,977)(4,815)(5,604)(16,898)
Net loss:(17,292)(18,471)(48,977)(4,815)(5,604)(16,898)
Other undisclosed net loss attributable to parent    (2,049)  
Net loss attributable to parent:(17,292)(18,471)(48,977)(6,865)(5,604)(16,898)
Preferred stock dividends and other adjustments (167)(329)  (426)(2,583)
Net loss available to common stockholders, diluted:(17,459)(18,800)(48,977)(6,865)(6,030)(19,481)

Comprehensive Income ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(17,292)(18,471)(48,977)(4,815)(5,604)(16,898)
Other comprehensive income    7,034  
Other undisclosed comprehensive loss     (453)(2,533)
Comprehensive income (loss):(17,292)(18,471)(48,977)2,219(6,057)(19,431)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(200)(835)150   
Comprehensive income (loss), net of tax, attributable to parent:(17,492)(19,306)(48,826)2,219(6,057)(19,431)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: